Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMB-003 multiple ascending dose study in adults with ulcerative colitis
ACTRN12626001240336Phase 2Not yet recruiting
- Sponsor
- Melius MicroBiomics
- Start
- Nov 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EcN::ttr in autoimmune colitis (7 cohorts), sponsored by Melius MicroBiomics. Primary endpoints: Safety of multiple ascending doses of MMB-003, Tolerability of multiple ascending doses of MMB-003 and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
EcN::ttr
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ACTRN12626001240336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001240336.